Henry Ford Hospital study: Less prep needed for colonoscopy

May 02, 2010

DETROIT - Researchers at Henry Ford Hospital may have found a better way to prep patients for colonoscopy procedures so they no longer need to drink a gallon of prescribed fluids prior to the procedure.

The study found that patients who took a pill that is FDA-approved for chronic constipation as part of the colonoscopy prep only needed to drink half of the liquid previously required to cleanse the bowels.

While the combination did not improve polyp detection during the colonoscopy, researchers say it led to improved bowel preparation quality and was better tolerated by patients than the liquid mix of polyethylene glycol (PEG) and electrolytes alone.

"Most people say they don't want to have a colonoscopy because they find the preparation intolerable," says Chetan Pai, D.O., a Henry Ford Hospital gastroenterologist and lead author of the study.

"If physicians are able to offer a better way to prep, I think this will encourage more people to get the colonoscopies that may save their lives."

He explains that approximately 90 percent of colon cancer occurs in people over age 50, but these older adults tend to have difficulty drinking a gallon of electrolytes in preparation for the colonoscopy.

Study results will be presented May 2 at Digestive Diseases Week in New Orleans.

According to the National Cancer Institute, in 2009, more than 146,000 new cases of colon and rectal cancer were diagnosed and nearly 50,000 people died from the disease. However, colon cancer is one of the most preventable forms of cancer because if it is found early through a colonoscopy screening test, it can be stopped before it has spread.

The constipation drug lubiprostone - a chloride pump activator in tablet form - has been used anecdotally in patients unable to tolerate drinking a full gallon of PEG and electrolytes as part of the bowel cleansing preparation for colonoscopy.

To test the effectiveness of lubiprostone as part of colonoscopy prep, Henry Ford conducted a randomized, double-blind and placebo-controlled study of 126 patients.

Researchers looked at the tolerability of the combination of lubiprostone and electrolytes, as well as electrolytes alone, and whether it was possible to reduce the volume of electrolytes required for colon cleansing.
-end-
The study was funded by Sucampo Pharmaceuticals, Inc., the manufacturer of lubiprostone.

EMBARGOED FOR RELEASE 8 a.m., EST, Sunday, May 2, 2010

Henry Ford Health System

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.